![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
20
Cipla Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Olmesartan medoxomil, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2016-119 - Rev 02
This Chemical Type CEP, issued on December 12, 2019, remains in force until October 23, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 2600 associated with this CEP further emphasizes